尿崩症 中国就医指南

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the inability to concentrate urine, leading to excessive production of dilute urine (polyuria) and intense thirst (polydipsia). Unlike diabetes mellitus, DI is not related to blood glucose dysregulation but rather stems from defects in the antidiuretic hormone (ADH), also known as vasopressin, pathway. There are four primary subtypes: central (neurogenic) DI, caused by deficient ADH synthesis or secretion due to hypothalamic or pituitary damage; nephrogenic DI, resulting from renal resistance to ADH due to genetic mutations (e.g., AVPR2 or AQP2 genes) or acquired causes such as chronic lithium use, hypercalcemia, or hypokalemia; gestational DI, a transient form linked to placental vasopressinase overexpression during pregnancy; and primary polydipsia (dipsogenic DI), driven by abnormal thirst regulation and excessive water intake that suppresses ADH release. Pathophysiologically, impaired ADH signaling disrupts aquaporin-2 water channel trafficking in the renal collecting ducts, preventing water reabsorption and causing persistent urinary water loss—often exceeding 3–20 L per day. Epidemiologically, DI affects approximately 1 in 25,000 to 1 in 50,000 individuals globally, with central DI accounting for ~75% of cases. Incidence peaks in adults aged 30–50 years, though congenital forms present in infancy. Risk factors include traumatic brain injury, neurosurgery (especially transsphenoidal procedures), autoimmune hypophysitis, infiltrative diseases (e.g., sarcoidosis, histiocytosis), pituitary tumors (e.g., craniopharyngioma), and long-term lithium therapy. Genetic forms—particularly X-linked nephrogenic DI—predominate in pediatric populations. Untreated DI significantly impairs quality of life: patients experience sleep disruption from nocturia, fatigue, cognitive fog, anxiety around fluid access, and social withdrawal. Chronic dehydration risks include electrolyte imbalances (notably hypernatremia), acute kidney injury, and, in vulnerable populations (e.g., elderly or cognitively impaired), delirium or seizures. Early diagnosis requires careful differentiation from psychogenic polydipsia and diabetes mellitus via serum sodium, plasma osmolality, urine osmolality, and formal water deprivation testing with desmopressin challenge. Misdiagnosis is common and delays appropriate management, underscoring the need for specialized endocrinology evaluation.

# 尿崩症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：中枢性尿崩症轻中度患者、肾性尿崩症稳定期、妊娠相关尿崩症。

• •药物治疗（一线）：

- 氢氯噻嗪+阿米洛利联合：25–60元/月

• •检查费：血钠、血渗透压、禁水-加压素试验、垂体MRI（增强）：共1,200–2,800元

二、手术/介入治疗方案

适用人群：明确由垂体/下丘脑占位（如颅咽管瘤、生殖细胞瘤）所致中枢性尿崩症，且经影像及动态激素评估证实需干预者。

• •神经内镜经鼻蝶窦微创手术（根治性切除）：

- 手术+麻醉+住院（7–14天）：48,000–72,000元 - 术后垂体功能替代及长期随访管理：首年约3,000–6,000元

三、特殊复杂情况处理

• •耐药性肾性尿崩症：布美他尼联合低钠饮食+个体化补钾，年药费8,000–15,000元；基因检测（AVPR2/SLC12A1）：2,600元
• •晚期电解质紊乱合并肾损伤：需ICU监护、连续性肾脏替代治疗（CRRT），单日费用4,500–6,800元

方案快速选择指南

✅ 预算有限/初诊患者：首选去氨加压素+基础检查（总启动成本≤3,500元） ✅ 明确肿瘤病因：微创手术为根治首选（医保报销后自付约15,000–25,000元） ✅ 遗传性肾性尿崩症：终身药物+营养管理，避免手术干预